India, March 27 -- Takeda Canada Inc., the Canadian organization of Takeda Pharmaceutical Company Limited (TAK), Thursday has announced that Health Canada has extended the marketing authorization for HyQvia "normal immunoglobulin [human] 10% and recombinant human hyaluronidase solution" to include chronic inflammatory demyelinating polyneuropathy - CIDP as a maintenance therapy.
This approval allows HyQvia to be used after stabilization with intravenous immunoglobulin - IVIG to prevent relapse of neuromuscular disability and impairment in adults.
HyQvia is the only subcutaneous immunoglobulin infusion in Canada that can be administered as infrequently as once every two, three, or four weeks. Patients have the option to receive the infusio...